Adults with Bardet-Biedl syndrome (BBS) generally report poorer physical, general, and social well-being than the general population, according to a study from Norway. Still, most patients show no clinically significant problems in everyday executive functioning — the mental skills used to plan, organize, prioritize, and regulate behavior — despite frequent…
News
A newly published expert review has confirmed trial data — from a late-stage study dubbed TRANSCEND — showing that treatment with Imcivree (setmelanotide) helps promote weight loss and reduce hunger in people with acquired hypothalamic obesity (aHO). The original findings from the Phase 3 TRANSCEND trial (NCT05774756),…
A Race Against Blindness, a nonprofit dedicated to funding research into Bardet-Biedl syndrome (BBS) and other inherited conditions that cause childhood blindness, is running a fundraising raffle where participants will have the chance to win a new car and thousands in cash. The Second Chance Lexus Overtrail…
Surgical treatment and the extent of brain damage are key factors linked to a high risk of acquired hypothalamic obesity (AHO) in children with tumors affecting the hypothalamus, according to a new study. The research reveals that nearly half of these pediatric patients develop AHO, with the condition emerging…
Treatment with Imcivree (setmelanotide), Rhythm Pharmaceuticals’ approved injection therapy for acquired hypothalamic obesity (aHO), helped children and adults with the rare obesity disorder lose body weight over as long as 2.5 years, according to new data from clinical trials. In addition, Rhythm‘s experimental oral treatment bivamelagon…
People with Bardet-Biedl syndrome (BBS) show a wide range of cognitive skills, but verbal skills do not seem to represent a particular weakness compared with other intellectual skills, according to a study based on standard intelligence quotient (IQ) tests. Lower scores on nonverbal tasks may be partly explained by…
Imcivree (setmelanotide) reduced the risk of metabolic complications such as diabetes or steatotic liver disease in people with acquired hypothalamic obesity (aHO), according to new analyses from a global clinical trial. In real-world analyses, Imcivree was also associated with reductions in body mass index (BMI) — a…
A team of international medical specialists and patient-led organizations has developed a simplified decision-making process incorporating updated clinical and genetic evidence to help clinicians worldwide reach a timely and accurate diagnosis of Bardet-Biedl syndrome (BBS). The development of the new evidence-based diagnostic algorithm was described in the study, “…
Palatin Technologies plans to move two experimental obesity-targeting therapies into clinical testing for Bardet-Biedl syndrome (BBS) and hypothalamic obesity (HO) over the next two years, with the launch of early trials involving people with BBS and HO. The drug candidates will also be developed as potential treatments for…
The European Commission (EC) has approved Imcivree (setmelanotide) to treat obesity and control hunger in people ages 4 years or older with acquired hypothalamic obesity (aHO) caused by damage to the brain’s appetite-control center. “This EC authorization is an important step toward making the first new treatment option available…
Recent Posts
- Adults with BBS report poorer physical, general, and social well-being
- How OCD took over my life, and what I did to get it back, part 2
- What people don’t understand about my son’s hypothalamic obesity
- Expert review confirms trial findings for approved aHO weight loss drug
- How OCD took over my life, and what I did to get it back, part 1